3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
21
Gynecologic
7
Gastrointestinal
4
Sarcoma
2
Genitourinary
2
Thoracic
1
Head & Neck
1
Dermatologic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Urologic Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Laryngeal Diseases
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
30
Docetaxel
10
Cetuximab
10
Trastuzumab
9
Paclitaxel
7
Nivolumab
6
Magnetic Resonance Spectroscopy
6
palbociclib
5
cemiplimab
5
Gemcitabine
5
Cyclophosphamide
5
Carboplatin
5
Capecitabine
5
Biopsy
5
durvalumab
4
atezolizumab
4
Surveys and Questionnaires
4
Radiotherapy
4
Fulvestrant
4
Fluorodeoxyglucose F18
4
Drug Therapy
4
Cisplatin
4
selpercatinib
3
poly ICLC
3
pazopanib
3
fludarabine
3
avelumab
3
Taxes
3
Sunitinib
3
Specimen Handling
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
niraparib
×
Head & Neck
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts